ArticleNPJ Parkinson's disease2025
Capsaicin and nicotine alleviate MPTP induced olfactory dysfunction by suppressing cGAS/TBK1/STING and MAPK mediated neuroinflammation.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Olfactory dysfunction serves as a potential early diagnostic biomarker for Parkinson's disease (PD), providing essential evidence for investigating PD pathogenesis and developing neuroprotective strategies. Capsaicin (CAP) and nicotine (Nic), pungent flavor compounds derived from Solanaceae plants, exhibit anti-inflammatory properties. Epidemiological studies indicate that higher levels of chili pepper consumption and smoking are inversely associated with PD risk. However, the mechanisms of CAP and Nic against PD-related olfactory dysfunction remain unclear. In this study, we observed that CAP and Nic ameliorated olfactory dysfunction in MPTP intranasal-treated PD mice and alleviated dopaminergic damage in key brain regions including the olfactory bulb, anterior olfactory nucleus, striatum and substantia nigra. Both compounds suppressed microglial activation in these regions, downregulated IL-6 expression, and upregulated TGF-β protein levels. Furthermore, our findings demonstrated that CAP and Nic could effectively mitigate MPTP-induced olfactory deficits by attenuating neuroinflammation mediated through the cGAS/TBK1/STING and MAPK signaling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.